Metformin, other antidiabetic drugs, and endometrial cancer risk

a nested case–control study within Italian healthcare utilization databases

Matteo Franchi, Rosario Asciutto, Federica Nicotra, Luca Merlino, Carlo la Vecchia, Giovanni Corrao, Cristina Bosetti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited. We investigated this issue using data from a nested case–control study within the healthcare utilization databases of the Lombardy Region, Italy. This study included 376 diabetic women with endometrial cancer and 7485 diabetic controls matched for cases on age, date at cohort entry, and duration of follow-up. We used conditional logistic regression models to estimate the odds ratio (OR) of endometrial cancer in relation to use of antidiabetic drugs, adjusted for the Charlson’s comorbidity index, selected medical conditions, prescription of selected drugs, and concomitant use of other antidiabetic drugs. At cohort entry, no significant associations were observed for metformin [OR=0.99, 95% confidence interval (CI) 0.80–1.23], sulfonylureas (OR=1.14, 95% CI 0.91–1.42), insulin (OR=0.72, 95% CI 0.34–1.56), and other antidiabetic drugs (OR=1.21, 95% CI 0.75–1.95). When we considered use during follow-up, a borderline significant excess risk was found for metformin (OR=1.30, 95% CI 1.00–1.70). However, this estimate decreased to 1.07 (95% CI 0.82–1.41) when taking into account BMI using a Monte Carlo sensitivity analysis. No significant associations were found for sulfonylureas (OR=1.16, 95% CI 0.91–1.47), thiazolidinediones (OR=0.77, 95% CI 0.48–1.24), repaglinide (OR=1.32, 95% CI 0.94–1.87), incretins (OR=1.21, 95% CI 0.63–2.32), and insulin (OR=1.19, 95% CI 0.82–1.71). Our data indicate that metformin, insulin, and other antidiabetic drugs did not meaningfully affect the risk of endometrial cancer.

Original languageEnglish
Pages (from-to)225-231
JournalEuropean Journal of Cancer Prevention
Volume26
DOIs
Publication statusPublished - 2017

Fingerprint

Metformin
Endometrial Neoplasms
Hypoglycemic Agents
Odds Ratio
Databases
Confidence Intervals
Delivery of Health Care
repaglinide
Insulin
Logistic Models
Incretins
Thiazolidinediones
Prescription Drugs
Type 2 Diabetes Mellitus
Italy
Comorbidity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Metformin, other antidiabetic drugs, and endometrial cancer risk : a nested case–control study within Italian healthcare utilization databases. / Franchi, Matteo; Asciutto, Rosario; Nicotra, Federica; Merlino, Luca; la Vecchia, Carlo; Corrao, Giovanni; Bosetti, Cristina.

In: European Journal of Cancer Prevention, Vol. 26, 2017, p. 225-231.

Research output: Contribution to journalArticle

Franchi, Matteo ; Asciutto, Rosario ; Nicotra, Federica ; Merlino, Luca ; la Vecchia, Carlo ; Corrao, Giovanni ; Bosetti, Cristina. / Metformin, other antidiabetic drugs, and endometrial cancer risk : a nested case–control study within Italian healthcare utilization databases. In: European Journal of Cancer Prevention. 2017 ; Vol. 26. pp. 225-231.
@article{8bd8019e91d44affbc3f6dc23f8d3631,
title = "Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested case–control study within Italian healthcare utilization databases",
abstract = "Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited. We investigated this issue using data from a nested case–control study within the healthcare utilization databases of the Lombardy Region, Italy. This study included 376 diabetic women with endometrial cancer and 7485 diabetic controls matched for cases on age, date at cohort entry, and duration of follow-up. We used conditional logistic regression models to estimate the odds ratio (OR) of endometrial cancer in relation to use of antidiabetic drugs, adjusted for the Charlson’s comorbidity index, selected medical conditions, prescription of selected drugs, and concomitant use of other antidiabetic drugs. At cohort entry, no significant associations were observed for metformin [OR=0.99, 95{\%} confidence interval (CI) 0.80–1.23], sulfonylureas (OR=1.14, 95{\%} CI 0.91–1.42), insulin (OR=0.72, 95{\%} CI 0.34–1.56), and other antidiabetic drugs (OR=1.21, 95{\%} CI 0.75–1.95). When we considered use during follow-up, a borderline significant excess risk was found for metformin (OR=1.30, 95{\%} CI 1.00–1.70). However, this estimate decreased to 1.07 (95{\%} CI 0.82–1.41) when taking into account BMI using a Monte Carlo sensitivity analysis. No significant associations were found for sulfonylureas (OR=1.16, 95{\%} CI 0.91–1.47), thiazolidinediones (OR=0.77, 95{\%} CI 0.48–1.24), repaglinide (OR=1.32, 95{\%} CI 0.94–1.87), incretins (OR=1.21, 95{\%} CI 0.63–2.32), and insulin (OR=1.19, 95{\%} CI 0.82–1.71). Our data indicate that metformin, insulin, and other antidiabetic drugs did not meaningfully affect the risk of endometrial cancer.",
author = "Matteo Franchi and Rosario Asciutto and Federica Nicotra and Luca Merlino and {la Vecchia}, Carlo and Giovanni Corrao and Cristina Bosetti",
year = "2017",
doi = "10.1097/CEJ.0000000000000235",
language = "English",
volume = "26",
pages = "225--231",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Metformin, other antidiabetic drugs, and endometrial cancer risk

T2 - a nested case–control study within Italian healthcare utilization databases

AU - Franchi, Matteo

AU - Asciutto, Rosario

AU - Nicotra, Federica

AU - Merlino, Luca

AU - la Vecchia, Carlo

AU - Corrao, Giovanni

AU - Bosetti, Cristina

PY - 2017

Y1 - 2017

N2 - Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited. We investigated this issue using data from a nested case–control study within the healthcare utilization databases of the Lombardy Region, Italy. This study included 376 diabetic women with endometrial cancer and 7485 diabetic controls matched for cases on age, date at cohort entry, and duration of follow-up. We used conditional logistic regression models to estimate the odds ratio (OR) of endometrial cancer in relation to use of antidiabetic drugs, adjusted for the Charlson’s comorbidity index, selected medical conditions, prescription of selected drugs, and concomitant use of other antidiabetic drugs. At cohort entry, no significant associations were observed for metformin [OR=0.99, 95% confidence interval (CI) 0.80–1.23], sulfonylureas (OR=1.14, 95% CI 0.91–1.42), insulin (OR=0.72, 95% CI 0.34–1.56), and other antidiabetic drugs (OR=1.21, 95% CI 0.75–1.95). When we considered use during follow-up, a borderline significant excess risk was found for metformin (OR=1.30, 95% CI 1.00–1.70). However, this estimate decreased to 1.07 (95% CI 0.82–1.41) when taking into account BMI using a Monte Carlo sensitivity analysis. No significant associations were found for sulfonylureas (OR=1.16, 95% CI 0.91–1.47), thiazolidinediones (OR=0.77, 95% CI 0.48–1.24), repaglinide (OR=1.32, 95% CI 0.94–1.87), incretins (OR=1.21, 95% CI 0.63–2.32), and insulin (OR=1.19, 95% CI 0.82–1.71). Our data indicate that metformin, insulin, and other antidiabetic drugs did not meaningfully affect the risk of endometrial cancer.

AB - Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited. We investigated this issue using data from a nested case–control study within the healthcare utilization databases of the Lombardy Region, Italy. This study included 376 diabetic women with endometrial cancer and 7485 diabetic controls matched for cases on age, date at cohort entry, and duration of follow-up. We used conditional logistic regression models to estimate the odds ratio (OR) of endometrial cancer in relation to use of antidiabetic drugs, adjusted for the Charlson’s comorbidity index, selected medical conditions, prescription of selected drugs, and concomitant use of other antidiabetic drugs. At cohort entry, no significant associations were observed for metformin [OR=0.99, 95% confidence interval (CI) 0.80–1.23], sulfonylureas (OR=1.14, 95% CI 0.91–1.42), insulin (OR=0.72, 95% CI 0.34–1.56), and other antidiabetic drugs (OR=1.21, 95% CI 0.75–1.95). When we considered use during follow-up, a borderline significant excess risk was found for metformin (OR=1.30, 95% CI 1.00–1.70). However, this estimate decreased to 1.07 (95% CI 0.82–1.41) when taking into account BMI using a Monte Carlo sensitivity analysis. No significant associations were found for sulfonylureas (OR=1.16, 95% CI 0.91–1.47), thiazolidinediones (OR=0.77, 95% CI 0.48–1.24), repaglinide (OR=1.32, 95% CI 0.94–1.87), incretins (OR=1.21, 95% CI 0.63–2.32), and insulin (OR=1.19, 95% CI 0.82–1.71). Our data indicate that metformin, insulin, and other antidiabetic drugs did not meaningfully affect the risk of endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=84969922058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969922058&partnerID=8YFLogxK

U2 - 10.1097/CEJ.0000000000000235

DO - 10.1097/CEJ.0000000000000235

M3 - Article

VL - 26

SP - 225

EP - 231

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

ER -